Akero Therapeutics presents positive Phase 2b trial results for EFX in MASH

From GlobeNewswire: 2025-05-10 10:00:00

Akero Therapeutics announced results from the Phase 2b HARMONY trial of EFX in patients with pre-cirrhotic MASH, showcasing antifibrotic activity. Digital pathology analysis revealed more than half of patients treated with EFX classified as responders compared to placebo patients. The study highlighted the potential of AI-based qFibrosis® in differentiating treatment effects from placebo noise. The data were presented at the European Association for the Study of the Liver Congress 2025. EFX is currently being evaluated in three Phase 3 studies for MASH treatment. The Phase 2b HARMONY study enrolled 128 patients with fibrosis stage 2 or 3, showing promising results in fibrosis improvement and MASH resolution.



Read more at GlobeNewswire: Akero Therapeutics and HistoIndex Present New Analyses of